Press releases
DexTech Medical informs about the myeloma study, the first patient is treated
13 December, 2023The Phase 1 study investigates the efficacy of OsteoDex in patients with progressive multiple myeloma (MM). The first patient is treated during week 50 at Karolinska University Hospital in Huddinge. […]
Bulletin from the Annual General Meeting
31 October, 2023Today, October 31, 2023, the Annual General Meeting of DexTech Medical AB was held. All resolutions were passed with the required majority. Resolution on adoption of the income statement and […]
Interim report July 1- September 30, 2023
27 October, 2023Summary of the first quarter (2023-07-01 – 2023-09-30) Net sales amounted to MSEK 0,0 (0,0) Operating profit/loss amounted to MSEK -1,1 (-0,8) Earnings per share* SEK -0.05 (-0.04) Cash and […]
DexTech Medical files a new patent application with the European Patent Office
13 October, 2023Dextech has filed a new patent application regarding GMP production (Good Manufacturing Practice) of the company’s lead candidate OsteoDex with the European Patent Office (EPO.Org). The application describes a GMP […]
Dextech Medical AB (publ) Notice to AGM 2023
29 September, 2023WELCOME TO THE ANNUAL GENERAL MEETING 2023 DEXTECH MEDICAL AB (publ) Dextech Medical AB’s shareholders are welcome to attend the Annual General Meeting Tuesday 31 October 2023 at 10.00 in […]
Dextech Medical AB Annual report 220701-230630
20 September, 2023Download the annual report below. DexTech Medical AB Ånnual report 220701-230630
Year-end report July 1, 2021 – June 30, 2022
30 August, 2023By “Company” or “DexTech” is meant DexTech Medical AB with organization number 556664-6203. Summary of the fourth quarter (2022-04-01 – 2022-06-30) Net sales amounted to MSEK 0,0 (0,0) Operating profit/loss […]
Interim report July 1, 2022 – March 31, 2023
28 April, 2023By “Company” or “DexTech” is meant DexTech Medical AB with organization number 556664-6203. Summary of the third quarter (2023-01-01 – 2023-03-31) Patient recruitment has begun for the Multiple Myeloma study […]
DexTech Medical informerar om myelomstudien
27 March, 2023Bolagets Fas 1-studie avseende effekt av OsteoDex på patienter med multipelt myelom (MM) har initierats och rekrytering av patienter påbörjats. Studien omfattar 20 patienter och genomförs initialt vid tre sjukhus […]
Half-year report July 1 – December 31, 2022
15 February, 2023Summary of the second quarter (2022-10-01 – 2022-12-31) Net sales amounted to MSEK 0,0 (0,0) Operating profit/loss amounted to MSEK -1,2 (-1,1) Earnings per share* SEK -0.06 (-0.08) * Before […]